KSM Feed

Our new COVID-19 4th shot study continues to make headlines.

Our Deputy Head Dr. Sivan Gazit on Channel 13 evening news.

The 4th dose of the BNT162b2 vaccine provides at least 73% protection against SARS-CoV-2 severe illness relative to three doses.

Our collaboration in genetic research with the United Arab Emirates.

First collaboration in genetic research between Israel and the United Arab Emirates.

82% decreased risk of reinfection among persons who were infected and then vaccinated.

Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes.

Galit Perez, head of KSM clinical trials, was chosen by Globes magazine to the annual list of most promosing leaders.

Waning of SARS-CoV-2 booster viral-load reduction effectiveness.

Dr. Sivan Gazit, Deputy Head of KSM, was chosen by TheMarker as one of the most promising leaders under 40.

Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine.

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two and Three doses of Vaccine.

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections.

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two and Three doses of Vaccine.

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections.